Advisory Board

Helen has over twenty-five years’ experience in the Medical device industry including as CEO of Creganna Medical and Product Development and Research roles at Medtronic and Covidien. She has demonstrated the ability to scale, including driving international sales, acquiring and integrating companies, establishing strategic joint ventures and raising of debt and equity financing. During her eight years as CEO of Creganna Medical, the company grew five-fold to become the largest indigenous medical device company.

She now works with Irish companies supporting them to start and scale. She acts as a strategic advisor to Atlantic Bridge Ventures and serves as a director for Enterprise Ireland. She works as an advisor and director for a number of early stage and scaling companies and charities.

Professor Lewis, formerly VP R&D at BTG/Boston Scientific (Biocompatibles UK Ltd.) specializes in the development of advanced biomedical polymer systems, including novel drug-device combination products for use in interventional therapies in the treatment of cardiovascular disease and cancer.

Many of his patented polymer systems have been successfully taken to market; directly or through license agreements. He led the development of the first commercial drug-eluting bead (DEB) technology for the locoregional treatment of malignancies in the liver. The DEB technology is now available globally with hundreds of thousands of procedures having now been performed.

Andy is a recognized expert on biomaterials; having generated over 250 scientific peer-reviewed publications and articles, 12 book chapters and 56 patent families/applications in the fields of polymers, biomaterials and drug delivery with 30+ granted patents in the field of embolization. He also peer-reviews manuscripts for over 25 journals.

Dr Isaacson received his medical degree from the Keck School of Medicine in Los Angeles before completing his diagnostic and interventional radiology training at the University of North Carolina. Dr Isaacson has been a pioneer in the field of embolization.

He worked with the FDA to get approval for and was the co-principal investigator of the first US GAE clinical trial for the treatment of knee osteoarthritis. He went on to be the principal investigator of the pioneering first US sham trial for GAE which definitively demonstrated patient benefit of GAE.

He is a co-director of the highly acclaimed STREAM embolization course; the only conference dedicated exclusively to embolization. He has published a number of peer-reviewed articles on GAE. He currently has a clinical practice in Raleigh, North Carolina and acts as the Chair of Quality and Research for Prostate Centers USA.

Dr. Little is a consultant Interventional Radiologist, and research lead working in Berkshire and London, UK. Dr. Little has established a large embolotherapy research group alongside his busy clinical practice. Dr. Little is currently leading the first European study investigating Genicular Artery Embolization (GAE) in the treatment of knee OA (GENESIS).

He is UK CI for PROstate, an international study investigating long term outcomes of PAE. He is current specialist advisor on the National Institute for Health & Care Excellence (NICE) interventional procedures programme including developing guidelines for GAE in clinical practice. Dr. Little is also a member of the CVIR editorial board.